Caroline Barelle | Chief Executive Officer
Elasmogen

Caroline Barelle, Chief Executive Officer, Elasmogen

Caroline is CEO and co-founder of Elasmogen, a company that discovers and develops soloMER biologics for the treatment of inflammatory diseases and cancer. Before establishing Elasmogen, she successfully led teams at Wyeth and subsequently Pfizer in Global Bio-therapeutic Technologies progressing early platform technologies to late stage clinical development. Prior to this she was Alliance and Programs Manager at Haptogen Ltd and a key part of the acquisition team that successfully exited the business to Wyeth Inc. She has been awarded a prestigious Royal Society of Edinburgh Enterprise Fellowship, is a doctoral graduate from the University of Aberdeen in Biochemistry and an MBA (distinction) from Robert Gordon’s University, Business School.

Appearances:



Festival of Biologics Day 3 @ 11:50

The unique epitope targeting ability of soloMERs

last published: 31/Jan/23 09:55 GMT
last published: 31/Jan/23 09:55 GMT

back to speakers